Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.
Group 3Pharmaceutical Industries
Novartis International AGNovartis was createdin 1996 from the       Type                            Public AGmerger of Cib...
MissionWe want to discover, develop and successfully market innovative products toprevent and cure diseases, to ease suffe...
Stakeholder                                                                                  prevent and cure diseases    ...
Objective Description   Measure   Target   Initiative
Strategy Map For Novaritis
Strategy Map For Novaritis
Strategy Map For Novaritis
Upcoming SlideShare
Loading in …5
×

Strategy Map For Novaritis

715 views

Published on

Anyone who need to download this file can request by providing the email.

  • Be the first to comment

  • Be the first to like this

Strategy Map For Novaritis

  1. 1. Group 3Pharmaceutical Industries
  2. 2. Novartis International AGNovartis was createdin 1996 from the Type Public AGmerger of Ciba- SIX: NOVN, NYSE: NVSGeigy and Sandoz Industry PharmaceuticalsLaboratories, both Founded 1996 (from merger)Swiss companies Headquarters Basel, Switzerlandwith long histories. Key people Daniel Vasella (Chairman),JosephCiba-Geigy was Jimenez (CEO)formed in 1970 by Products Pharmaceuticals, genericthe merger of J. R. drugs, over-the-counterGeigy Ltd (founded drugs, vaccines, diagnostics,contactin Basel in 1758) lenses, animal health(list...)and CIBA (founded Revenue US $50.624 billion (2010)in Basel in 1859). Operating income US $11.526 billion (2010)Combining the Net income US $9.969 billion (2010)histories of the Total assets US $123.32 billion (end 2010)merger partners, the Total equity US $69.769 billion (end 2010)companys effectivehistory spans 250 Employees 119,418 (FTE, end 2010)years Subsidiaries Ciba Vision, Sandoz, Alcon Website novartis.com
  3. 3. MissionWe want to discover, develop and successfully market innovative products toprevent and cure diseases, to ease suffering and to enhance the quality oflife.We also want to provide a shareholder return that reflects outstandingperformance and to adequately reward those who invest ideas and work inour company.Research and developmentThe major bases for R&D are Basel, Shanghai,and Boston. Operations in China are set for rapid expansionwithin the next five years.Major therapeutic areas areautoimmunity/transplantation/inflammatory disease,cardiovascular disease, diabetes, gastrointestinal disease,infectious diseases, musculoskeletal disease, neuroscience,oncology, ophthalmology, and respiratory disease.
  4. 4. Stakeholder prevent and cure diseases Full range of healthcare options enhance the quality of life. Outcomes Prevention Drivers Self-care Innovative medicines Affordable options ManufacturingInternal Process Distribution Marketing Outcomes DriversLearning & Growth Cardiovascular and Metabolism Oncology Respiratory Immunology and Infectious Diseases Neuroscience and Ophthalmics Outcomes Rejuvenate the Pharmaportfolio Build world-leading platform in eye care Drivers Accelerate growth of non-Pharma businesses Focused diversification in healthcare Expand in high-growth markets Strengthening franchises with specific needsInvestments Outcomes Drivers Vaccines and Diagnostics Pharmaceuticals Consumer Health (OTC, Animal Health and CIBA Vision)
  5. 5. Objective Description Measure Target Initiative

×